Make me a presentation on management of acute pancreatic for post graduate clinics
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Searching PubMed
"acute pancreatitis" management guidelines
Reading File
Running Command
mkdir -p /home/daytona/workspace/acute-pancreatitis-pptx && ls /home/daytona/wor…
Writing File
~/acute-pancreatitis-pptx/build.js
const pptxgen = require("pptxgenjs");
const pres = new pptxgen();
pres.layout = "LAYOUT_WIDE";
pres.title = "Management of Acute Pancreatitis";
pres.author = "Postgraduate Clinic";
// ── COLOUR PALETTE ──────────────────────────────────────────────────────────
const C = {
navy: "0A1628", // dominant dark
teal: "0E7C7B", // primary accent
gold: "F4A828", // secondary accent
slate: "2C3E50", // mid-dark body
ice: "EBF5F5", // content bg light
white: "FFFFFF",
red: "C0392B",
orange: "E67E22",
green: "1A9E5C",
grey: "7F8C8D",
lightgrey: "ECF0F1",
};
// ── HELPERS ──────────────────────────────────────────────────────────────────
function titleSlide(title, subtitle) {
const sl = pres.addSlide();
// dark gradient-effect bg
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: "100%", fill: { color: C.navy } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: 0.08, fill: { color: C.teal } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 7.42, w: "100%", h: 0.08, fill: { color: C.gold } });
// decorative circle
sl.addShape(pres.ShapeType.ellipse, { x: 9.5, y: -1, w: 4, h: 4, fill: { color: C.teal }, line: { color: C.teal }, transparency: 70 });
sl.addText(title, {
x: 0.7, y: 1.6, w: 11, h: 2.0,
fontSize: 40, bold: true, color: C.white, fontFace: "Calibri",
align: "left", valign: "middle",
});
if (subtitle) {
sl.addText(subtitle, {
x: 0.7, y: 3.8, w: 10, h: 0.7,
fontSize: 20, color: C.gold, fontFace: "Calibri", align: "left",
});
}
sl.addText("IAP/APA 2025 • ACG 2024 • Schwartz's Surgery • Maingot's Abdominal Operations", {
x: 0.7, y: 6.8, w: 11, h: 0.4,
fontSize: 11, color: C.grey, fontFace: "Calibri", align: "left",
});
return sl;
}
function sectionDivider(title, subtitle) {
const sl = pres.addSlide();
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: "100%", fill: { color: C.teal } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 0.12, h: "100%", fill: { color: C.gold } });
sl.addShape(pres.ShapeType.ellipse, { x: 8, y: 3.5, w: 6, h: 6, fill: { color: C.navy }, transparency: 80 });
sl.addText(title, {
x: 0.6, y: 2.3, w: 11.5, h: 1.4,
fontSize: 36, bold: true, color: C.white, fontFace: "Calibri",
});
if (subtitle) {
sl.addText(subtitle, {
x: 0.6, y: 3.9, w: 11.5, h: 0.8,
fontSize: 18, color: C.lightgrey, fontFace: "Calibri",
});
}
return sl;
}
function contentSlide(title, bullets, opts = {}) {
const sl = pres.addSlide();
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: "100%", fill: { color: C.white } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: 0.85, fill: { color: C.navy } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0.85, w: "100%", h: 0.06, fill: { color: C.gold } });
sl.addText(title, {
x: 0.3, y: 0.1, w: 12.7, h: 0.75,
fontSize: 22, bold: true, color: C.white, fontFace: "Calibri", valign: "middle",
});
const items = bullets.map((b, i) => {
if (b.startsWith("##")) {
return { text: b.replace("## ", ""), options: { bold: true, color: C.teal, fontSize: 14, bullet: false, breakLine: true, paraSpaceBefore: 8 } };
}
if (b.startsWith("!")) {
return { text: b.replace("! ", ""), options: { bold: true, color: C.red, fontSize: 13, bullet: { type: "number" }, breakLine: true } };
}
return { text: b, options: { color: C.slate, fontSize: 13, bullet: { indent: 20 }, breakLine: true } };
});
sl.addText(items, {
x: 0.4, y: 1.05, w: opts.w || 12.5, h: opts.h || 5.8,
fontFace: "Calibri", valign: "top",
});
return sl;
}
function twoColSlide(title, leftTitle, leftBullets, rightTitle, rightBullets) {
const sl = pres.addSlide();
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: "100%", fill: { color: C.white } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: 0.85, fill: { color: C.navy } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0.85, w: "100%", h: 0.06, fill: { color: C.gold } });
sl.addText(title, {
x: 0.3, y: 0.1, w: 12.7, h: 0.75,
fontSize: 22, bold: true, color: C.white, fontFace: "Calibri", valign: "middle",
});
// left col
sl.addShape(pres.ShapeType.rect, { x: 0.3, y: 1.05, w: 5.9, h: 5.9, fill: { color: C.ice }, line: { color: C.teal, width: 1.5 } });
sl.addText(leftTitle, { x: 0.5, y: 1.1, w: 5.6, h: 0.45, fontSize: 14, bold: true, color: C.teal, fontFace: "Calibri" });
const lItems = leftBullets.map(b => ({ text: b, options: { color: C.slate, fontSize: 12.5, bullet: { indent: 18 }, breakLine: true } }));
sl.addText(lItems, { x: 0.5, y: 1.58, w: 5.5, h: 5.2, fontFace: "Calibri", valign: "top" });
// right col
sl.addShape(pres.ShapeType.rect, { x: 7.1, y: 1.05, w: 5.9, h: 5.9, fill: { color: C.ice }, line: { color: C.gold, width: 1.5 } });
sl.addText(rightTitle, { x: 7.3, y: 1.1, w: 5.6, h: 0.45, fontSize: 14, bold: true, color: C.orange, fontFace: "Calibri" });
const rItems = rightBullets.map(b => ({ text: b, options: { color: C.slate, fontSize: 12.5, bullet: { indent: 18 }, breakLine: true } }));
sl.addText(rItems, { x: 7.3, y: 1.58, w: 5.5, h: 5.2, fontFace: "Calibri", valign: "top" });
return sl;
}
function tableSlide(title, tableData, colWidths, opts = {}) {
const sl = pres.addSlide();
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: "100%", fill: { color: C.white } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: 0.85, fill: { color: C.navy } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0.85, w: "100%", h: 0.06, fill: { color: C.gold } });
sl.addText(title, {
x: 0.3, y: 0.1, w: 12.7, h: 0.75,
fontSize: 22, bold: true, color: C.white, fontFace: "Calibri", valign: "middle",
});
sl.addTable(tableData, {
x: 0.3, y: 1.05, w: 13, h: opts.h || 5.9,
colW: colWidths,
fontSize: 12, fontFace: "Calibri",
border: { type: "solid", pt: 0.5, color: "CCCCCC" },
autoPage: false,
});
return sl;
}
// ── HEADER ROW HELPER ────────────────────────────────────────────────────────
function hdr(text, colspan) {
return { text, options: { bold: true, color: C.white, fill: C.navy, align: "center", colspan } };
}
function cell(text, fill, color, bold) {
return { text, options: { fill: fill || C.white, color: color || C.slate, bold: !!bold, align: "left", valign: "middle" } };
}
function cellC(text, fill, color, bold) {
return { text, options: { fill: fill || C.white, color: color || C.slate, bold: !!bold, align: "center", valign: "middle" } };
}
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 1 — TITLE
// ═══════════════════════════════════════════════════════════════════════════
titleSlide(
"Management of\nAcute Pancreatitis",
"A Postgraduate Clinical Review"
);
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 2 — OVERVIEW / AGENDA
// ═══════════════════════════════════════════════════════════════════════════
{
const sl = pres.addSlide();
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: "100%", fill: { color: C.navy } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 0.12, h: "100%", fill: { color: C.teal } });
sl.addText("Lecture Overview", {
x: 0.5, y: 0.4, w: 12, h: 0.7,
fontSize: 28, bold: true, color: C.white, fontFace: "Calibri",
});
const topics = [
"1. Definition, Epidemiology & Burden",
"2. Etiology & Pathophysiology",
"3. Clinical Presentation & Diagnosis",
"4. Severity Classification (Atlanta / RAC)",
"5. Prognostic Scoring Systems",
"6. Initial Management & Resuscitation",
"7. Nutritional Support",
"8. Pharmacotherapy & Antibiotics",
"9. ERCP Timing in Gallstone Pancreatitis",
"10. Local Complications & Interventions",
"11. Systemic Complications & ICU Care",
"12. Special Scenarios & Discharge Planning",
];
const items = topics.map(t => ({ text: t, options: { color: C.ice, fontSize: 14, bullet: false, breakLine: true, paraSpaceBefore: 5 } }));
sl.addText(items, { x: 0.5, y: 1.3, w: 12.3, h: 5.8, fontFace: "Calibri", valign: "top" });
}
// ═══════════════════════════════════════════════════════════════════════════
// SECTION 1 DIVIDER
// ═══════════════════════════════════════════════════════════════════════════
sectionDivider("Section 1", "Definition, Epidemiology & Etiology");
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 3 — DEFINITION & EPIDEMIOLOGY
// ═══════════════════════════════════════════════════════════════════════════
contentSlide("Definition & Epidemiology", [
"## Definition (Revised Atlanta Classification 2012)",
"Acute inflammatory disease of the pancreas, diagnosed by ≥2 of 3 criteria:",
"Abdominal pain consistent with AP (acute-onset severe constant epigastric pain, often radiating to the back)",
"Serum amylase or lipase > 3× upper limit of normal",
"Characteristic imaging findings on CT / MRI",
"## Epidemiology",
"Incidence: 13–45 per 100,000 population per year (increasing globally)",
"Commonest GI cause of hospital admission in many countries",
"Mortality: Overall < 3% (mild); severe AP carries 20–30% mortality",
"80% mild (interstitial edematous); 20% moderate–severe (necrotizing)",
"## Atlanta Severity Classification",
"Mild AP: No organ failure, no local or systemic complications",
"Moderately severe AP: Transient organ failure (<48 h) AND/OR local complications",
"Severe AP: Persistent organ failure (>48 h) — single or multi-organ",
]);
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 4 — ETIOLOGY (two-col)
// ═══════════════════════════════════════════════════════════════════════════
twoColSlide(
"Etiology of Acute Pancreatitis",
"Common Causes (>80%)",
[
"Gallstones (biliary) — 40–70%",
"Alcohol — 25–35%",
"Idiopathic — 10–15%",
"Hypertriglyceridemia (TG > 1000 mg/dL)",
"Post-ERCP — 3–5% of all procedures",
"Medications (azathioprine, valproate, didanosine, furosemide)",
],
"Less Common / Rare Causes",
[
"Hypercalcaemia (hyperparathyroidism)",
"Pancreatic divisum",
"Sphincter of Oddi dysfunction",
"Trauma / blunt abdominal injury",
"Autoimmune pancreatitis (IgG4-related)",
"Ampullary / pancreatic tumours",
"Hereditary: PRSS1, SPINK1, CFTR mutations",
"Infections: mumps, CMV, HIV",
"Ischaemia / vasculitis",
]
);
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 5 — PATHOPHYSIOLOGY
// ═══════════════════════════════════════════════════════════════════════════
contentSlide("Pathophysiology — Key Mechanisms", [
"## Acinar Cell Injury (Common Final Pathway)",
"Premature trypsinogen activation → trypsin overwhelms protective mechanisms",
"Lysosomal (cathepsin B) and zymogen granule colocalization — critical initiating event",
"Cytosolic Ca²⁺ rise required for colocalization and NF-κB activation",
"## Local Cascade",
"Trypsin activates other zymogens → autodigestion of pancreatic parenchyma",
"Acinar cell necrosis → neutrophil recruitment → amplified inflammation",
"Pancreatic microvascular failure → hypoperfusion → necrosis",
"Interstitial edematous pancreatitis (no necrosis) vs. Necrotizing pancreatitis",
"## Systemic Cascade (SIRS → MOF)",
"NF-κB activation → pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, PAF)",
"Mesenteric lymph bypasses liver → systemic inflammatory spread",
"Cytokine storm → ARDS, AKI, cardiovascular failure, DIC",
"Two-peak mortality pattern: early SIRS/MOF vs. late septic complications",
]);
// ═══════════════════════════════════════════════════════════════════════════
// SECTION 2 DIVIDER
// ═══════════════════════════════════════════════════════════════════════════
sectionDivider("Section 2", "Clinical Presentation, Diagnosis & Severity Scoring");
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 6 — CLINICAL FEATURES & DIAGNOSIS
// ═══════════════════════════════════════════════════════════════════════════
twoColSlide(
"Clinical Presentation & Diagnosis",
"Clinical Features",
[
"Severe, constant epigastric pain — radiation to back",
"Nausea, vomiting (common)",
"Low-grade fever",
"Tachycardia, tachypnea, hypotension (severe)",
"Abdominal guarding / peritonism",
"Cullen's sign — periumbilical ecchymosis",
"Grey Turner's sign — flank ecchymosis",
"Tetany (hypocalcaemia)",
"Jaundice (if biliary aetiology)",
],
"Investigations",
[
"Serum lipase — more specific (preferred); >3× ULN",
"Serum amylase — peaks 2–12 h; normalises by 3–5 days",
"LFTs, bilirubin, ALP — biliary aetiology",
"FBC, CRP (>150 mg/L at 48 h → severe)",
"BUN/creatinine, blood glucose, calcium",
"ABG — if respiratory compromise",
"USS abdomen — gallstones, CBD dilation",
"CECT — if diagnosis uncertain OR at 48–72 h if severe",
"MRCP — if suspected choledocholithiasis",
]
);
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 7 — CECT SCORING
// ═══════════════════════════════════════════════════════════════════════════
{
const sl = pres.addSlide();
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: "100%", fill: { color: C.white } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: 0.85, fill: { color: C.navy } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0.85, w: "100%", h: 0.06, fill: { color: C.gold } });
sl.addText("CECT: Balthazar Grading & CT Severity Index (CTSI)", {
x: 0.3, y: 0.1, w: 12.7, h: 0.75,
fontSize: 22, bold: true, color: C.white, fontFace: "Calibri", valign: "middle",
});
// Balthazar table
sl.addText("Balthazar Grade", { x: 0.3, y: 1.05, w: 6, h: 0.4, fontSize: 14, bold: true, color: C.teal, fontFace: "Calibri" });
sl.addTable([
[cellC("Grade", C.teal, C.white, true), cellC("CT Finding", C.teal, C.white, true), cellC("Points", C.teal, C.white, true)],
[cellC("A"), cell("Normal pancreas"), cellC("0")],
[cellC("B"), cell("Focal / diffuse enlargement"), cellC("1")],
[cellC("C"), cell("Peripancreatic fat inflammation"), cellC("2")],
[cellC("D"), cell("Single fluid collection"), cellC("3")],
[cellC("E"), cell("≥2 fluid collections or gas"), cellC("4")],
], { x: 0.3, y: 1.5, w: 6, h: 2.8, colW: [1.2, 3.5, 1.3], fontSize: 12, fontFace: "Calibri",
border: { type: "solid", pt: 0.5, color: "CCCCCC" } });
sl.addText("Necrosis Score", { x: 7.0, y: 1.05, w: 6, h: 0.4, fontSize: 14, bold: true, color: C.orange, fontFace: "Calibri" });
sl.addTable([
[cellC("Necrosis", C.orange, C.white, true), cellC("Points", C.orange, C.white, true)],
[cell("No necrosis"), cellC("0")],
[cell("< 30%"), cellC("2")],
[cell("30–50%"), cellC("4")],
[cell("> 50%"), cellC("6")],
], { x: 7.0, y: 1.5, w: 5.8, h: 2.8, colW: [4, 1.8], fontSize: 12, fontFace: "Calibri",
border: { type: "solid", pt: 0.5, color: "CCCCCC" } });
sl.addShape(pres.ShapeType.rect, { x: 0.3, y: 4.55, w: 12.5, h: 0.06, fill: { color: C.teal } });
sl.addText("CTSI = Balthazar points + Necrosis points (max 10)", {
x: 0.3, y: 4.7, w: 12.5, h: 0.4, fontSize: 14, bold: true, color: C.teal, fontFace: "Calibri",
});
sl.addTable([
[cellC("CTSI Score", C.navy, C.white, true), cellC("Severity", C.navy, C.white, true), cellC("Morbidity", C.navy, C.white, true), cellC("Mortality", C.navy, C.white, true)],
[cellC("0–3"), cell("Mild"), cellC("8%"), cellC("3%")],
[cellC("4–6"), cell("Moderate"), cellC("35%"), cellC("6%")],
[cellC("7–10", C.red, C.white), cell("Severe", C.red, C.white), cellC("92%", C.red, C.white), cellC("17%", C.red, C.white)],
], { x: 0.3, y: 5.2, w: 12.5, h: 1.6, colW: [3, 3.5, 3, 3], fontSize: 12, fontFace: "Calibri",
border: { type: "solid", pt: 0.5, color: "CCCCCC" } });
}
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 8 — SEVERITY SCORING (Ranson & BISAP)
// ═══════════════════════════════════════════════════════════════════════════
{
const sl = pres.addSlide();
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: "100%", fill: { color: C.white } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: 0.85, fill: { color: C.navy } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0.85, w: "100%", h: 0.06, fill: { color: C.gold } });
sl.addText("Prognostic Scoring: Ranson Criteria & BISAP", {
x: 0.3, y: 0.1, w: 12.7, h: 0.75,
fontSize: 22, bold: true, color: C.white, fontFace: "Calibri", valign: "middle",
});
// Ranson
sl.addText("Ranson Criteria", { x: 0.3, y: 1.0, w: 7, h: 0.4, fontSize: 14, bold: true, color: C.teal, fontFace: "Calibri" });
sl.addTable([
[hdr("On Admission", 1), hdr("At 48 Hours", 1)],
[cell("Age > 55 years"), cell("Haematocrit fall > 10%")],
[cell("WBC > 16,000/mm³"), cell("BUN rise > 5 mg/dL")],
[cell("Blood glucose > 200 mg/dL"), cell("Serum Ca²⁺ < 8 mg/dL")],
[cell("LDH > 350 IU/L"), cell("PaO₂ < 60 mmHg")],
[cell("AST > 250 IU/L"), cell("Base deficit > 4 mEq/L")],
[cell(""), cell("Fluid sequestration > 6 L")],
], { x: 0.3, y: 1.45, w: 7.5, h: 3.2, colW: [3.7, 3.8], fontSize: 12, fontFace: "Calibri",
border: { type: "solid", pt: 0.5, color: "CCCCCC" } });
sl.addText("Score ≥3 → severe disease (mortality 10–15%); Score ≥5 → mortality > 40%", {
x: 0.3, y: 4.75, w: 7.5, h: 0.5, fontSize: 11.5, italic: true, color: C.grey, fontFace: "Calibri",
});
// BISAP
sl.addText("BISAP Score (1 point each)", { x: 8.3, y: 1.0, w: 5, h: 0.4, fontSize: 14, bold: true, color: C.orange, fontFace: "Calibri" });
sl.addTable([
[hdr("BISAP Parameter", 1)],
[cell("B — BUN > 25 mg/dL")],
[cell("I — Impaired mental status")],
[cell("S — SIRS criteria ≥2")],
[cell("A — Age > 60 years")],
[cell("P — Pleural effusion on imaging")],
], { x: 8.3, y: 1.45, w: 4.9, h: 2.5, colW: [4.9], fontSize: 12, fontFace: "Calibri",
border: { type: "solid", pt: 0.5, color: "CCCCCC" } });
sl.addText("BISAP ≥3 → severe AP; Mortality up to 22%", {
x: 8.3, y: 4.0, w: 4.9, h: 0.4, fontSize: 11.5, italic: true, color: C.grey, fontFace: "Calibri",
});
sl.addShape(pres.ShapeType.rect, { x: 0.3, y: 5.3, w: 12.5, h: 0.06, fill: { color: C.gold } });
sl.addText("APACHE II ≥8 also identifies severe AP with ≥25% mortality. Best used in ICU settings.", {
x: 0.3, y: 5.5, w: 12.5, h: 0.4, fontSize: 12, bold: true, color: C.teal, fontFace: "Calibri",
});
}
// ═══════════════════════════════════════════════════════════════════════════
// SECTION 3 DIVIDER
// ═══════════════════════════════════════════════════════════════════════════
sectionDivider("Section 3", "Initial Management & Resuscitation");
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 9 — INITIAL MANAGEMENT
// ═══════════════════════════════════════════════════════════════════════════
contentSlide("Initial Management — First 24 Hours", [
"## Admission & Triage",
"All patients with suspected AP should be admitted to hospital",
"Mild AP → General ward; Moderate–Severe → HDU/ICU",
"Reassess at 24 h and 48 h — severity can escalate",
"## IV Fluid Resuscitation (Goal-Directed)",
"Aggressive IV fluid resuscitation — cornerstone of early management",
"Preferred: Lactated Ringer's (LR) — reduces systemic inflammation vs. normal saline (ACG 2024 / IAP 2025)",
"Rate: 250–500 mL/h titrated to clinical response (HR, MAP, urine output)",
"Target: UO > 0.5 mL/kg/h; BUN decrease; haematocrit 35–44%",
"Avoid: Over-resuscitation → abdominal compartment syndrome",
"## Pain Management",
"Priority — early adequate analgesia",
"IV NSAIDs (e.g. metamizole 2 g/8 h IV) for mild pain",
"Opioid analgesia for severe pain: buprenorphine, pentazocine, pethidine",
"! Morphine avoided — risk of sphincter of Oddi spasm",
"Thoracic epidural analgesia may reduce complications in severe AP",
]);
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 10 — NUTRITION
// ═══════════════════════════════════════════════════════════════════════════
twoColSlide(
"Nutritional Support in Acute Pancreatitis",
"Key Principles",
[
"Gut rest is OUTDATED — early enteral nutrition is preferred",
"Enteral route maintains gut barrier, reduces bacterial translocation",
"Reduces infectious complications and mortality (vs. TPN)",
"Start EN within 24–48 h if tolerated",
"Mild AP — resume oral diet (low-fat) as soon as pain improves & appetite returns",
"Severe AP — early nasojejunal (NJ) or nasogastric (NG) tube feeding",
"NJ vs NG — both are acceptable (IAP/APA 2025)",
],
"Parenteral Nutrition (TPN)",
[
"Reserve TPN only when enteral route is not feasible",
"Enteral feeding within 72 h of onset is preferred over TPN",
"Indications for TPN:",
" ↳ Ileus preventing enteral feeding",
" ↳ Fistulas preventing enteral access",
" ↳ Bowel obstruction",
"Monitor for hyperglycaemia — tight glycaemic control",
"Supplemental glutamine may be considered in TPN",
]
);
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 11 — ANTIBIOTICS & PHARMACOTHERAPY
// ═══════════════════════════════════════════════════════════════════════════
contentSlide("Antibiotics & Pharmacotherapy", [
"## Antibiotics — Current Evidence (ACG 2024 / IAP 2025)",
"! Prophylactic antibiotics are NOT recommended in sterile AP or sterile necrosis",
"Multiple RCTs and meta-analyses showed no benefit from prophylactic antibiotics",
"Antibiotics indicated ONLY when:",
" ↳ Infected necrotizing pancreatitis (confirmed or strongly suspected)",
" ↳ Extra-pancreatic infection (cholangitis, pneumonia, UTI, bacteraemia)",
"## Antibiotic Choice for Infected Necrosis",
"Carbapenems (imipenem/meropenem) — excellent pancreatic penetration",
"Fluoroquinolones (ciprofloxacin) + metronidazole — alternative",
"Duration: guided by clinical response and source control",
"## Other Pharmacotherapy",
"Antifungals: consider if prolonged antibiotics, immunosuppression, or fungal infection suspected",
"Somatostatin / octreotide — evidence does NOT support routine use",
"Protease inhibitors (gabexate, nafamostat) — insufficient evidence for routine use",
"Proton pump inhibitors — use only for stress ulcer prophylaxis in critically ill",
]);
// ═══════════════════════════════════════════════════════════════════════════
// SECTION 4 DIVIDER
// ═══════════════════════════════════════════════════════════════════════════
sectionDivider("Section 4", "Biliary Pancreatitis, Local Complications & Interventions");
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 12 — ERCP IN BILIARY PANCREATITIS
// ═══════════════════════════════════════════════════════════════════════════
contentSlide("ERCP Timing in Gallstone (Biliary) Pancreatitis", [
"## Indications for Urgent ERCP (within 24 h)",
"Acute cholangitis complicating gallstone pancreatitis — URGENT ERCP",
"Obstructive jaundice with CBD stone on imaging — ERCP within 24–48 h",
"## Mild Biliary AP Without Cholangitis",
"Urgent ERCP does NOT reduce complications — not routinely recommended",
"However, persistent biliary obstruction warrants early ERCP",
"## Cholecystectomy",
"Same-admission laparoscopic cholecystectomy for mild biliary AP (reduces recurrence)",
"For severe AP — defer cholecystectomy until inflammation resolves (≥6 weeks)",
"Cholecystectomy should be performed before discharge in mild AP (ACG 2024)",
"## Prevention of Post-ERCP Pancreatitis",
"Rectal indomethacin (100 mg) — reduces post-ERCP pancreatitis risk",
"Prophylactic pancreatic stent placement — high-risk patients",
"Wire-guided cannulation technique preferred over contrast injection",
]);
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 13 — LOCAL COMPLICATIONS TABLE
// ═══════════════════════════════════════════════════════════════════════════
{
const sl = pres.addSlide();
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: "100%", fill: { color: C.white } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: 0.85, fill: { color: C.navy } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0.85, w: "100%", h: 0.06, fill: { color: C.gold } });
sl.addText("Revised Atlanta Classification — Local Complications", {
x: 0.3, y: 0.1, w: 12.7, h: 0.75,
fontSize: 22, bold: true, color: C.white, fontFace: "Calibri", valign: "middle",
});
sl.addTable([
[hdr("Timing", 1), hdr("<4 weeks — No Defined Wall", 2), hdr(">4 weeks — Defined Wall", 2)],
[hdr("Content", 1), hdr("Without Infection", 1), hdr("With Infection", 1), hdr("Without Infection", 1), hdr("With Infection", 1)],
[
cell("Fluid only", C.ice),
cell("Acute Pancreatic Fluid Collection (APFC)", C.ice),
cell("Infected APFC", C.ice),
cell("Pseudocyst", C.ice),
cell("Infected Pseudocyst", C.ice),
],
[
cell("Solid ± Fluid", C.lightgrey),
cell("Acute Necrotic Collection (ANC)", C.lightgrey),
cell("Infected ANC", C.lightgrey),
cell("Walled-Off Necrosis (WON)", C.lightgrey),
cell("Infected WON", C.lightgrey),
],
], {
x: 0.3, y: 1.05, w: 12.8, h: 2.8,
colW: [2, 2.7, 2.5, 2.7, 2.9],
fontSize: 12, fontFace: "Calibri",
border: { type: "solid", pt: 0.5, color: "CCCCCC" },
});
sl.addText("Key Points", { x: 0.3, y: 4.1, w: 12.5, h: 0.4, fontSize: 14, bold: true, color: C.teal, fontFace: "Calibri" });
const notes = [
"APFCs and ANCs occur in the first 4 weeks; most APFCs resolve spontaneously — drainage NOT indicated",
"Pseudocysts develop after 4 weeks; asymptomatic pseudocysts → observe; symptomatic → drainage (endoscopic preferred)",
"WON = pancreatic necrosis + defined wall after 4 weeks; infected WON = indication for intervention",
"Diagnosis of infected necrosis: CT-guided FNA (gas in collection is pathognomonic) + clinical deterioration",
];
const noteItems = notes.map(n => ({ text: n, options: { color: C.slate, fontSize: 12.5, bullet: { indent: 18 }, breakLine: true } }));
sl.addText(noteItems, { x: 0.4, y: 4.55, w: 12.5, h: 2.5, fontFace: "Calibri", valign: "top" });
}
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 14 — MANAGEMENT OF NECROSIS & INTERVENTION
// ═══════════════════════════════════════════════════════════════════════════
contentSlide("Management of Pancreatic Necrosis & Infected Collections", [
"## Principle: Step-Up Approach (IAP/APA 2025 / ACG 2024)",
"Delay intervention as long as possible — preferably ≥4 weeks (for WON to mature)",
"Conservative management with antibiotics for 2–4 weeks before intervention",
"## Step 1 — Percutaneous/Endoscopic Drainage",
"EUS-guided transmural drainage (cystogastrostomy / cystoduodenostomy) — PREFERRED for WON",
"Percutaneous catheter drainage — if WON not accessible endoscopically",
"Lumen-apposing metal stents (LAMS) — increasingly used for EUS drainage",
"## Step 2 — Minimally Invasive Necrosectomy",
"Video-assisted retroperitoneal debridement (VARD)",
"Endoscopic necrosectomy (direct endoscopy through stent tract)",
"Repeated lavage sessions often required for infected WON",
"## Step 3 — Open Surgical Necrosectomy (reserved)",
"Only if minimally invasive approaches fail",
"High morbidity and mortality — last resort",
"Open necrosectomy: minimal access retroperitoneal, laparoscopic, or open laparotomy",
]);
// ═══════════════════════════════════════════════════════════════════════════
// SECTION 5 DIVIDER
// ═══════════════════════════════════════════════════════════════════════════
sectionDivider("Section 5", "Systemic Complications, ICU Care & Special Scenarios");
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 15 — SYSTEMIC COMPLICATIONS
// ═══════════════════════════════════════════════════════════════════════════
twoColSlide(
"Systemic Complications & ICU Management",
"Major Systemic Complications",
[
"ARDS / ALI — most common organ failure",
" ↳ Mechanical ventilation, lung-protective strategy",
"Acute Kidney Injury (AKI)",
" ↳ Aggressive fluid resuscitation, avoid nephrotoxins",
" ↳ RRT if persistent oliguria/anuria",
"Cardiovascular failure / shock",
" ↳ Vasopressors (noradrenaline first-line)",
"Disseminated Intravascular Coagulation (DIC)",
"Hypocalcaemia — calcium gluconate IV",
"Hyperglycaemia — insulin infusion (target 7.8–10 mmol/L)",
"Paralytic ileus",
"Splenic / portal vein thrombosis",
],
"ICU Care Priorities",
[
"Early organ support — do not delay ICU transfer",
"Continuous monitoring: A-line, CVP, urinary catheter",
"SOFA score monitoring — serial assessment",
"Modified fluid resuscitation after first 48 h — avoid fluid overload",
"DVT prophylaxis (LMWH) once haemorrhagic risk assessed",
"Stress ulcer prophylaxis (PPI / H₂ blocker)",
"Enteral nutrition via NGT/NJT",
"Abdominal compartment syndrome:",
" ↳ Bladder pressure monitoring",
" ↳ Decompressive laparotomy if IAP > 20 mmHg + new organ failure",
]
);
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 16 — VASCULAR & HAEMORRHAGIC COMPLICATIONS
// ═══════════════════════════════════════════════════════════════════════════
contentSlide("Vascular & Haemorrhagic Complications", [
"## Pseudoaneurysm (PA)",
"Complicates 1–2% of severe AP — erosion of peripancreatic vessels",
"Splenic artery most common (65%); also gastroduodenal, pancreaticoduodenal arteries",
"Presentation: sudden haematocrit drop, expanding collection, haemobilia",
"Diagnosis: CECT with angiography",
"Management: Angioembolisation — first-line; surgery if embolisation fails",
"## Splenic / Portal / Mesenteric Vein Thrombosis",
"Complicates 1–24% of severe AP",
"Splenic vein thrombosis most common → left-sided (segmental) portal hypertension",
"Anticoagulation for symptomatic portal vein thrombosis",
"## Haemorrhagic Pancreatitis",
"Haemorrhage into retroperitoneum or peritoneal cavity",
"Massive haemorrhage: embolisation or surgical control",
"Requires surgical assessment if haemodynamically unstable",
]);
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 17 — SPECIAL SCENARIOS
// ═══════════════════════════════════════════════════════════════════════════
twoColSlide(
"Special Clinical Scenarios",
"Hypertriglyceridaemia-Induced AP",
[
"TG > 1000 mg/dL — significant risk; >2000 mg/dL — severe",
"Management:",
" ↳ Insulin infusion (activates lipoprotein lipase)",
" ↳ Heparin infusion (short-term, controversial)",
" ↳ Plasmapheresis/apheresis — rapid TG reduction",
" ↳ Restrict fat intake once feeding resumes",
"Long-term: fibrates (gemfibrozil), omega-3s, diet",
"Avoid oestrogen, thiazides, retinoids (precipitants)",
],
"Pregnancy & Recurrent AP",
[
"Biliary AP most common in pregnancy",
"MRCP preferred (avoid radiation)",
"ERCP + sphincterotomy if choledocholithiasis",
"Cholecystectomy deferred to second trimester or post-partum",
"LR fluid preferred — safe in pregnancy",
"",
"Recurrent Acute Pancreatitis:",
" ↳ Investigate for genetic causes (PRSS1, SPINK1, CFTR)",
" ↳ Autoimmune: IgG4, ANA, serology",
" ↳ MRCP / EUS for structural lesions",
" ↳ Risk of progression to chronic pancreatitis",
]
);
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 18 — DISCHARGE & FOLLOW-UP
// ═══════════════════════════════════════════════════════════════════════════
contentSlide("Discharge Criteria & Follow-Up", [
"## Discharge Criteria (Mild AP)",
"Oral intake tolerated (low-fat diet) without pain",
"Significant improvement in pain and inflammatory markers",
"Absence of complications requiring continued hospital care",
"Afebrile and haemodynamically stable",
"## Cholecystectomy Timing",
"Mild biliary AP → same admission or within 2 weeks of discharge (reduces recurrence from 30% to <1%)",
"Severe/necrotising AP → defer until resolution (minimum 6–8 weeks)",
"## Follow-Up",
"4–6 week review: repeat imaging (USS/CT) for fluid collections",
"Assess for exocrine pancreatic insufficiency: steatorrhoea, weight loss → PERT (pancreatic enzyme replacement)",
"Screen for new-onset diabetes mellitus (Type 3c diabetes)",
"Counsel on alcohol cessation, dietary modification, weight management",
"## Long-Term Risk",
"Recurrence risk: 20–35% if underlying cause not addressed",
"Progression to chronic pancreatitis in 10–20% (especially alcohol-related)",
]);
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 19 — MANAGEMENT ALGORITHM
// ═══════════════════════════════════════════════════════════════════════════
{
const sl = pres.addSlide();
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: "100%", fill: { color: C.white } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: 0.85, fill: { color: C.navy } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0.85, w: "100%", h: 0.06, fill: { color: C.gold } });
sl.addText("Management Algorithm — Acute Pancreatitis", {
x: 0.3, y: 0.1, w: 12.7, h: 0.75,
fontSize: 22, bold: true, color: C.white, fontFace: "Calibri", valign: "middle",
});
// Box helper
function box(sl, x, y, w, h, text, fill, color, fontSize) {
sl.addShape(pres.ShapeType.roundRect, { x, y, w, h, fill: { color: fill || C.teal }, line: { color: fill || C.teal }, rectRadius: 0.08 });
sl.addText(text, { x: x + 0.06, y, w: w - 0.12, h, fontSize: fontSize || 11, color: color || C.white, fontFace: "Calibri", bold: true, align: "center", valign: "middle" });
}
function arrow(sl, x, y, w, h) {
sl.addShape(pres.ShapeType.line, { x, y, w, h, line: { color: C.grey, width: 1.5 } });
}
box(sl, 5.2, 1.05, 3, 0.55, "SUSPECTED ACUTE PANCREATITIS", C.navy, C.white, 10);
arrow(sl, 6.7, 1.6, 0, 0.3);
box(sl, 4.5, 1.95, 4.5, 0.55, "Confirm Diagnosis (Pain + Lipase/Amylase >3×ULN ± CT)", C.slate, C.white, 10);
arrow(sl, 6.7, 2.5, 0, 0.3);
box(sl, 4.5, 2.85, 4.5, 0.55, "Admit + Severity Assessment\n(Ranson, BISAP, APACHE II, CTSI)", C.teal, C.white, 10);
// Two branches
arrow(sl, 5.2, 3.4, -1.8, 0); // left
arrow(sl, 8.1, 3.4, 1.8, 0); // right
box(sl, 2.0, 3.4, 3, 0.7, "MILD AP\n(no organ failure, no necrosis)", C.green, C.white, 10);
box(sl, 8.5, 3.4, 3.8, 0.7, "MODERATE–SEVERE AP\n(organ failure / necrosis)", C.red, C.white, 10);
// Mild branch
sl.addText([
{ text: "• LR fluids 250–500 mL/h\n• Analgesia\n• Oral diet when tolerated\n• Treat underlying cause\n• Cholecystectomy (biliary)", options: { color: C.slate, fontSize: 10, breakLine: false } }
], { x: 1.8, y: 4.2, w: 3.4, h: 1.8, fontFace: "Calibri" });
// Severe branch
sl.addText([
{ text: "• HDU / ICU admission\n• Aggressive LR resuscitation\n• Early enteral nutrition\n• CECT at 48–72 h\n• Antibiotics ONLY if infected\n• Step-up approach for necrosis\n• ERCP if cholangitis / obstruction", options: { color: C.slate, fontSize: 10, breakLine: false } }
], { x: 8.5, y: 4.2, w: 4.5, h: 2.2, fontFace: "Calibri" });
sl.addText("Key: Both pathways require early aggressive IV fluid resuscitation and multimodal analgesia within the first hours.", {
x: 0.3, y: 6.8, w: 12.8, h: 0.5, fontSize: 11, italic: true, color: C.grey, fontFace: "Calibri",
});
}
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 20 — KEY TAKEAWAYS
// ═══════════════════════════════════════════════════════════════════════════
{
const sl = pres.addSlide();
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: "100%", fill: { color: C.navy } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: "100%", h: 0.06, fill: { color: C.teal } });
sl.addShape(pres.ShapeType.rect, { x: 0, y: 7.44, w: "100%", h: 0.06, fill: { color: C.gold } });
sl.addText("Key Takeaways", {
x: 0.5, y: 0.2, w: 12.5, h: 0.7,
fontSize: 26, bold: true, color: C.gold, fontFace: "Calibri",
});
const points = [
["01", "Diagnose with ≥2 of: pain + lipase/amylase >3×ULN + imaging. CT only needed if uncertain."],
["02", "Aggressive goal-directed IV fluid resuscitation with Lactated Ringer's is the cornerstone of early care."],
["03", "Severity stratification at admission and 48 h (Ranson/BISAP/APACHE II/CTSI) guides triage."],
["04", "Early enteral nutrition (within 24–48 h) is superior to TPN — start via NG or NJ tube in severe AP."],
["05", "Prophylactic antibiotics are NOT indicated in sterile necrotising pancreatitis — evidence does not support use."],
["06", "Step-up approach for infected necrosis: antibiotics → EUS/percutaneous drainage → minimally invasive necrosectomy."],
["07", "Biliary AP with cholangitis → urgent ERCP. Mild biliary AP → same-admission cholecystectomy."],
["08", "New IAP/APA 2025 & ACG 2024 guidelines endorse delayed intervention (≥4 weeks) for infected WON."],
];
points.forEach(([num, text], i) => {
const y = 1.1 + i * 0.78;
sl.addShape(pres.ShapeType.ellipse, { x: 0.3, y: y, w: 0.55, h: 0.55, fill: { color: C.teal } });
sl.addText(num, { x: 0.3, y: y, w: 0.55, h: 0.55, fontSize: 12, bold: true, color: C.white, fontFace: "Calibri", align: "center", valign: "middle" });
sl.addText(text, { x: 1.0, y: y + 0.04, w: 12, h: 0.5, fontSize: 12, color: C.ice, fontFace: "Calibri", valign: "middle" });
});
}
// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 21 — REFERENCES
// ═══════════════════════════════════════════════════════════════════════════
contentSlide("References & Guidelines", [
"## Clinical Guidelines",
"IAP/APA/EPC/IPC/JPS Working Group. Revised Guidelines on Acute Pancreatitis 2025. Pancreatology. 2025 Sep. [PMID: 40651900]",
"Tenner S, Vege SS, Sheth SG, et al. American College of Gastroenterology Guidelines: Management of Acute Pancreatitis. Am J Gastroenterol. 2024. [PMID: 38857482]",
"UK Working Party on Acute Pancreatitis. UK Guidelines for the Management of Acute Pancreatitis. Gut. 2005;54(Suppl III):1–9.",
"Banks PA et al. Classification of acute pancreatitis — 2012: revision of the Atlanta classification. Gut. 2013;62(1):102–11.",
"## Textbooks",
"Schwartz's Principles of Surgery, 11th Edition — Chapter 33: Pancreas",
"Maingot's Abdominal Operations, 12th Edition — Chapter 55: Complications of Acute Pancreatitis",
"Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 11th Edition",
"Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice",
"## Scoring Systems",
"Ranson JH. Etiological and prognostic factors in human acute pancreatitis. Am J Gastroenterol. 1979.",
"Wu BU et al. The early prediction of mortality in acute pancreatitis (BISAP). Gut. 2008;57(12):1608–14.",
"Balthazar EJ et al. Acute pancreatitis: value of CT in establishing prognosis. Radiology. 1990.",
]);
// ── WRITE FILE ───────────────────────────────────────────────────────────────
pres.writeFile({ fileName: "/home/daytona/workspace/acute-pancreatitis-pptx/Acute_Pancreatitis_PG.pptx" })
.then(() => console.log("DONE: Presentation saved."))
.catch(e => { console.error("ERROR:", e); process.exit(1); });
Editing File
~/acute-pancreatitis-pptx/build.js
Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/acute-pancreatitis-pptx/build.js'
Running Command
cat > /home/daytona/workspace/acute-pancreatitis-pptx/build.js << 'ENDOFSCRIPT' …
Running Command
cd /home/daytona/workspace/acute-pancreatitis-pptx && node build.js 2>&1
Running Command
ls -lh /home/daytona/workspace/acute-pancreatitis-pptx/Acute_Pancreatitis_PG.ppt…
Your presentation is ready:
Acute Pancreatitis PG
Presentation · PPTX
What's inside (20 slides, LAYOUT_WIDE 16:9)
The deck uses a navy/teal/gold clinical colour scheme designed for a postgraduate audience. Here is the full slide map:
| # | Slide | Content |
|---|---|---|
| 1 | Title | Management of Acute Pancreatitis — PG Clinical Review |
| 2 | Agenda | 12-point lecture overview |
| 3 | Definition & Epidemiology | Revised Atlanta 2012 criteria, incidence, mortality, severity categories |
| 4 | Etiology | Two-column: common causes (gallstones, alcohol, HTG, drugs) vs. rare causes |
| 5 | Pathophysiology | Acinar cell cascade, trypsinogen activation, NF-κB/cytokine storm, two-peak mortality |
| 6 | Presentation & Investigations | Clinical signs (Cullen's, Grey Turner's) + full investigation panel |
| 7 | CECT / CTSI | Balthazar grading table + necrosis score table + CTSI severity/mortality matrix |
| 8 | Prognostic Scoring | Ranson criteria (admission + 48 h) + BISAP + APACHE II note |
| 9 | Initial Management | Goal-directed LR fluids, monitoring targets, IV analgesia (morphine warning) |
| 10 | Nutrition | Early EN vs TPN — evidence, NG vs NJ, glycaemic control |
| 11 | Antibiotics & Drugs | No prophylactic antibiotics, indications, carbapenems, pharmacotherapy |
| 12 | ERCP Timing | Cholangitis → urgent ERCP, same-admission cholecystectomy, PEP prophylaxis |
| 13 | Local Complications Table | Revised Atlanta 4-category table (APFC/ANC/Pseudocyst/WON) + management notes |
| 14 | Step-Up Approach | PANTER trial principle, EUS/LAMS drainage, VARD, open surgery as last resort |
| 15 | Systemic Complications & ICU | ARDS/AKI/shock/DIC, abdominal compartment syndrome, ICU bundle |
| 16 | Special Scenarios | HTG-induced AP (insulin, plasmapheresis) + Pregnancy + Recurrent AP workup |
| 17 | Discharge & Follow-Up | Discharge criteria, cholecystectomy timing, PERT, Type 3c diabetes screening |
| 18 | Management Algorithm | Flowchart: suspected AP → diagnosis → mild vs. severe pathways |
| 19 | Key Takeaways | 8 numbered high-yield points for exam/clinical practice |
| 20 | References | IAP/APA 2025, ACG 2024, Revised Atlanta 2012, Schwartz's, Maingot's, Ranson, BISAP |
Sources used: Schwartz's Principles of Surgery (11e), Maingot's Abdominal Operations, Sleisenger & Fordtran, IAP/APA Revised Guidelines 2025 (PMID: 40651900), ACG Guidelines 2024 (PMID: 38857482).
This is a shared conversation. Sign in to Orris to start your own chat.